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manuscript.
Fig. 1. (D):
‘‘ZMYND8 mRNA expression in clinical prostate cancer speci-
mens (GSE3324 and GSE6909). n = 6–7, ⁄P < 0.05, ⁄⁄P < 0.01 vs.
normal tissue. #P < 0.05. GSE3324 and GSE6909 include 6–7
and 18–25 specimens at each stage, respectively’’.
should be changed to:
‘‘Immunostaining of human ZMYND8 in clinical prostate cancer
specimens’’.Fig. 1. (E):
‘‘Immunostaining of human ZMYND8 in clinical prostate cancer
specimens. n = 3–7, ⁄P < 0.05 vs. stage I, P < 0.01 vs. normal
tissue’’.
should be changed to:
‘‘Quantitative analysis of (D). n = 3–7, ⁄P < 0.05 vs. stage I, 
P < 0.01 vs. normal tissue’’.chool of
